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Introduction 
Heart failure is a syndrome resulting from a structural or functional cardiac disorder.  For a diagnosis 
of heart failure to be made, there should be symptoms or signs, such as breathlessness, effort 
intolerance or fluid retention, together with objective evidence of cardiac dysfunction.  
Heart failure is an increasingly important chronic disease syndrome, associated with poor prognosis, 
poor quality of life for patients, and high healthcare costs.1,w2 In the general population, where all 
grades of heart failure are represented, 5-year mortality is around 42%,3 but where the diagnosis is 
established during a hospital admission 5 year mortality is between 50-75%,4,w5
 
  although the 
prognosis has improved in the past ten years.  
Prevalence and incidence of heart failure 
Studies including objective assessment of left ventricular (LV) function, usually echocardiography, 
indicate a prevalence of left ventricular systolic dysfunction (LVSD) of 2.9% in patients under 756 
and up to 7.5% in 75 to 84 year olds.w7 In the largest recent prospective evaluation of heart failure 
in the community, definite heart failure was found in 2.3% (95% CI 1.9-2.8) of the population, with 
left ventricular ejection fraction (LVEF) less than 40% in 41% cases. However, if the LVEF cut off was 
set at under 50% rather than 40%, now advocated in some guidelines, 3.1% (95% CI 2.6%-3.7%) 
of people aged 45 or over were defined as having heart failure.8
 
  
Estimates on heart failure incidence are less available, and vary from 0.9-2.29
 
 per 1000 females (45-
74) per year and 1.6-4.6 men (45-74) per 1000 population per year. Incidence rises rapidly in the 
elderly, with 1% of men per year developing heart failure after 75 and almost 2% per year in over 
85s.  
The typical primary care physician, caring for 2000 patients, is likely to have 40-50 patients with 
heart failure (more if population is elderly), and to have 5 or so new cases of heart failure diagnosed 
each year, with the diagnosis being suspected in perhaps 3 times as many. The syndrome is, 
therefore, relatively common but not so frequent that the individual practitioner will become expert 
in diagnosis. Clear guidance is needed on which clinical features and combination of investigations is 
best to rule out or rule in heart failure in patients with new symptoms.  
 
Burden of heart failure on healthcare systems 
Chronic heart failure remains one of the most costly conditions to manage: the syndrome is 
common, it frequently results in hospital admission, admissions are long, and re-admission is 
frequent particularly where chronic disease management programmes are not running (nearly 25% 
of patients are readmitted within 12 weeks of discharge).10
 
 As a consequence, heart failure accounts 
for around 2% of total healthcare expenditure in most developed countries.  
Good diagnosis is the cornerstone of good management 
There is a huge evidence base for therapies that improve morbidity, global quality of life, and 
mortality in all grades of heart failure due to LVSD,11,12 and can delay LVSD progression to 
symptomatic heart failure.w13 Despite this extensive evidence, heart failure remains sub-optimally 
diagnosed and treated in many countries.w14
 
 An essential element for treatment success is the 
reliable and precise diagnosis of heart failure. 
Diagnostic issues in heart failure 
The evaluation of patients with suspected heart failure entails determining more than just whether 
the syndrome is present or not. It is important to identify the underlying cardiac pathologies, 
exacerbating or precipitating factors, and the whole body’s response to the cardiac dysfunction – 
including particularly renal function. Guidelines for the evaluation and management of heart failure 
have been published by professional societies in North America (American College of 
Cardiology/American Heart Association (ACC/AHA)15 and Consensus Recommendationsw16) and 
Europe (European Society of Cardiology).17 The latter state that the diagnosis of heart failure is 
justified when there are typical signs and symptoms of heart failure and myocardial dysfunction, 
confirmed by the objective evidence of cardiac dysfunction at rest. In case of diagnostic uncertainty, 
a clinical response to treatment directed at heart failure is helpful in establishing the diagnosis (Table 
1). Simple and reliable diagnostic procedures are very important for primary care physicians, who 
are responsible for the early diagnosis of heart failure and implementation of adequate therapy in 
most healthcare systems.  
 
Current NICE guidance on diagnosing heart failure 
The National Institute for Health and Clinical Excellence (NICE) guideline on chronic heart failure for 
primary and secondary care in England recommends that patients with suspected heart failure 
should have an electrocardiograph (ECG) and/or B-type natriuretic peptide (BNP or NT-proBNP) 
assay performed.18
 
 If both are normal, then heart failure is unlikely, and an alternative diagnosis to 
explain the symptoms should be considered. If either is abnormal, then the patient should have an 
echocardiogram, or other imaging test, to confirm underlying cardiac dysfunction. (Figure 1) This 
guidance was based on the high sensitivity of both plasma BNP and the ECG, and the result of a 
health economic analysis that demonstrated that the cost per life year gained through 
echocardiography is dependent upon the proportion of patients referred for echocardiography in 
whom the diagnosis of heart failure is confirmed.  
However, current diagnosis of heart failure in primary care is often inaccurate. In one recent UK 
study, only 34% of patients with an existing clinical label of heart failure in routine general practice 
records had this diagnosis confirmed at echocardiography and review.19
 
  
There have been seven recent systematic reviews relevant to the diagnosis of heart failure in 
primary care. Three covered all symptoms, signs and diagnostic tests, 18, 20,w21 three concerned BNP 
alone, 22,w23,w24  and one was a review of the accuracy of the 12 lead ECG.25
 
 
Symptoms and signs 
Individual symptoms (such as breathlessness, fatigue, exercise intolerance and fluid retention) and 
signs (such as resting tachycardia, raised jugular venous pressure (JVP), displaced apex beat, third 
heart sound) are generally weak predictors of heart failure, with poor reliability, and little agreement 
between clinicians on their presence or absence, even amongst specialists.  
 
In a recent systematic review, a number of symptoms were reasonably specific, including a history of 
myocardial infarction (89% specificity), orthopnoea (89%), cardiomegaly (85%), added heart sounds 
(99%), lung crepitations (81%), and hepatomegaly (97%) (Table 2). However, in primary care, the 
most useful symptoms/signs in diagnosis have high sensitivity, since this might enable the clinician 
to rule out heart failure if the symptom/sign was absent, without the need to refer for further 
investigation. Dyspnoea is the only clinical feature that comes close to this ideal with a sensitivity of 
87%. In practice this symptom is present in the majority of patients in whom heart failure is 
suspected, with a frequency as high as 95% in one of the datasets. Nevertheless, a sensitivity of 
87% is not high enough on its own to rule out heart failure if dyspnoea is absent. 
  
Investigations 
Both ECG25,w26,w27
 
 and BNP w21,22,w23 have high sensitivity for heart failure, and so are good tests at 
ruling out the diagnosis (Table 3). UK based studies restricted to use of ECG in primary care 
however, give a more mixed picture on the value of ECG, with sensitivity in one study as low as 
73%.25 These differences may relate to both differences in population characteristics, and to the skill 
of the practitioner interpreting the ECG. Similarly, while the chest x-ray may show evidence of heart 
failure (e.g. cardiomegaly, pulmonary vascular congestion), it is not a good independent predictor, 
and is of most value in identifying alternative causes of symptoms such as lung disease or pleural 
effusion.   
In a review of four studies that evaluated the diagnostic accuracy of the resting ECG in the specific 
context of referral from primary care to echocardiographic services, sensitivity of ECG varied from 
73% to 91%, and the authors concluded that the ECG was an inadequate screening tool.25 A review 
of the diagnostic accuracy of natriuretic peptides and ECG in the diagnosis of LVSD found similar 
diagnostic accuracy between ECG, BNP and NT-proBNP and no value from combining BNP with 
ECG.28
 
 A recent systematic review confirmed that adding ECG to clinical features plus plasma BNP 
result did not improve the accuracy of diagnosis.20 
It is likely that BNP is a more accurate test for heart failure than it is for LVSD. Indeed, a recent 
systematic review of BNP studies concluded that while BNP is useful for excluding heart failure, it is 
more limited for ruling out systolic dysfunction, with an AUC of 0.93 for heart failure but only 0.75 
for systolic dysfunction.29 There is no evidence of any significant differences in test performance 
between BNP and NT-proBNP.28,29 Other recent reviews of BNP have confirmed its value as a ‘rule 
out’ test for heart failure.w30,w31,w32
 
 
Echocardiography is the most readily available ‘reference standard’ investigation for LVSD and valve 
disease. Assessment of diastolic dysfunction can also be made on echocardiography,33
Role of clinical decision rules in the work up of patients with suspected heart failure 
 but the 
interpretation of the findings may be difficult, particularly in the elderly and in patients with atrial 
fibrillation (up to 30% of new cases of heart failure in most series). In practice today, ‘normal 
ejection fraction’ (‘preserved systolic function’, ‘diastolic’ or ‘non-systolic’) heart failure often remains 
a diagnosis of exclusion. Echocardiography after a plasma BNP test has been performed is an 
attractive option, particularly if the supply of echocardiography is limited or access is slow, though 
appropriate cut points for BNP (or NT-proBNP) are then needed.   
There are several well developed heart failure diagnostic tools which combine the results of different 
symptoms/signs and investigations. Mosterd et al applied criteria from six established HF scores 
including Framingham, Walma and Boston to a sample of 54 participants in the population-based 
Rotterdam study.34 Most showed high utility to detect definite heart failure with Areas Under the 
Receiver Operated Characteristic (ROC) Curve (AUC) ranging between 0.89 and 0.96. However, use 
of these would be impractical in routine primary care because of the substantial number of variables 
in several scores; and also because many of the clinical signs have considerable inter-observer 
variation even amongst specialists (raised JVP, third heart sound, hepatojugular reflux).w35,w36
 
 
Furthermore four of the scores include specific chest x-ray parameters difficult to apply in general 
practice.  
A recent meta-analysis using individual patient data identified a simple new diagnostic score. This 
rule suggests that in a patient presenting with new symptoms such as breathlessness in whom heart 
failure is suspected, if the patient has any one of: a) history of MI OR b) basal crepitations OR c) is a 
male with ankle oedema (so called MICE score), then it is appropriate to refer straight for 
echocardiography as the probability of heart failure is high. Otherwise, a plasma BNP test should be 
performed, and referral to echocardiography should be organised depending on the concentration of 
plasma BNP (Table 4).20  
 
Limitations of the evidence base 
There is no single ideal reference standard for heart failure, since there is no single cardiac disorder 
that accounts for the syndrome. The underlying cardiac disorders can be classified in different ways. 
The standard approach is to divide heart failure into low ejection fraction and normal ejection 
fraction heart failure, if significant valve disease has been excluded as the primary cause of the heart 
failure. Echocardiography is a suitable reference standard for low ejection fraction heart failure, but 
is not as robust for normal ejection fraction heart failure. The definitive tests to diagnose normal 
ejection fraction heart failure (pressure-volume measurements at cardiac catheterisation) are often 
not carried out, so the diagnosis usually relies upon clinical judgement and supportive evidence. 
 
Studies that have tested the value of the ECG in the diagnosis of heart failure have used different 
criteria with which to define abnormality, and there has been variation in the experience and 
expertise of the person reading the ECG. Many general practitioners are unable to interpret ECGs 
accurately. 
 
For natriuretic peptides, most of the existing research has been done on secondary care populations, 
or in the context of screening studies that identify prevalent cases of heart failure, or include patients 
with existing diagnoses of heart failure. This may introduce significant spectrum bias and affect 
whether the cut-off values are reliable for the target population, namely symptomatic patients 
presenting in primary care.  
 
Conclusions 
Heart failure is a clinical syndrome that may be difficult for a primary care physician to diagnose 
accurately, particularly if the symptoms develop slowly and are not so severe as to warrant 
immediate hospitalisation. Access to tests that can help rule out heart failure (such as plasma BNP or 
NT-proBNP) when combined with clinical assessment can be very useful to aid the physician’s 
investigation pathway. Patients likely to have heart failure after such initial assessment should 
undergo echocardiography, with expert interpretation, to help confirm the diagnosis and to 
determine the underlying cardiac pathophysiology. More detailed diagnostic work-up may also be 
required to fully characterise the syndrome and determine the appropriate management plan.  
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Main Points 
• Heart failure is difficult to diagnose in primary care 
• Early diagnosis can favourably alter prognosis and mortality 
• A number of symptoms and signs have some diagnostic value in the clinical assessment of a 
patient with suspected heart failure. Dyspnoea is the symptom with the highest sensitivity, 
but it is not sufficiently high that heart failure can be ruled out in its absence 
• ECG, BNP and NT-proBNP all have high sensitivity for heart failure 
• Head-to-head studies and systematic reviews suggest that BNP or NT-proBNP is a more 
accurate investigation than ECG for the diagnosis of heart failure.  
• There is no evidence that performing both BNP and ECG improves diagnosis of heart failure 
• There is no evidence of any significant difference in accuracy between different BNP assays 
• A simple clinical score based upon gender, history of MI, presence of oedema and presence of 
basal lung crepitations may help a physician discriminate between people with suspected 
heart failure who should be referred straight for echocardiography, and people for whom the 
diagnosis is less likely and should be confirmed by a BNP test before referral.  
Table 1. Definition of heart failure in the current ESC guidelines for the diagnosis and 
management of heart failure.17 
 
 
Heart failure is a syndrome in which patients have the following features: 
 
• Symptoms typical of heart failure 
(breathlessness at rest or on exertion, fatigue, tiredness, ankle swelling) 
 
AND 
 
• Signs typical of heart failure 
(tachycardia, tachypnoea, pulmonary rales, pleural effusion, raised jugular venous pressure, 
peripheral oedema, hepatomegaly) 
 
AND 
 
• Objective evidence of a structural or functional abnormality of the heart at rest 
(cardiomegaly, third heart sound, cardiac murmur, abnormality on the echocardiogram, 
raised natriuretic peptide concentration) 
 Table 2. Overall accuracy of clinical features of heart failure. 
 Number of Patients 
(studies) 
Sensitivity (%) Specificity (%) Youden Index* 
 
History of AMI  1769 (10) 26 89 15 
Dyspnoea 2187 (5) 87 51 38 
Orthopnoea 2901 (6) 44 89 33 
Paroxysmal 
nocturnal dyspnoea 
1786 (3) No summary results 
Oedema 3736 (12) 53 72 25 
Tachycardia 1582 (3) No summary results 
Elevated JVP  3353 (7) 52 70 22 
Cardiomegaly 405 (1) 27 85 12 
Added heart sounds 2948 (6) 11 99 10 
Lung crepitation 4619 (11) 51 81 32 
Hepatomegaly 1058 (1) 17 97 14 
 
* Youden index = Sensitivity % + specificity %- 100%.  This is a measure of the overall diagnostic 
accuracy of the test, with a maximum score of 100; AMI = Acute Myocardial Infarction 
 
 
Table 3. Overall accuracy of investigations for heart failure. 
 Number of Patients 
(studies) 
Sensitivity (%) Specificity (%) Youden Index* 
ECG 4702 (11) 89% 56% 45 
CXR: any 
abnormality 
2323 (5) 68% 83% 51 
CXR: increased 
cardio-thoracic ratio  
2797 (6) 67% 76% 43 
BNP 4744 (20) 93% 74% 67 
NT-proBNP 4229 (16) 93% 65% 58 
 
• Youden index = Sensitivity % + specificity %- 100%.  This is a measure of the overall 
diagnostic accuracy of the test; ECG + Electrocardiograph; CXR = Chest X Ray; BNP and NT-
proBNP = B Type natriuretic peptide and N Terminal pro B Type natriuretic peptide 
 
 
 Table 4. Simple clinical decision rule (MICE) developed in a UK Health Technology 
Assessment for the diagnosis of heart failure in primary care. 20 
 
 
 
Clinical rule 
 
In a patient presenting with symptoms in whom heart failure is suspected, refer straight to 
echocardiography if the patient has any one of: 
-history of MI, or 
-basal crepitations, or 
-male with ankle oedema 
 
Otherwise, carry out a BNP test, and refer for echocardiography depending on the results of the BNP:  
- Female without ankle oedema – refer for echocardiography if BNP > 210-360 pg/ml depending 
upon local availability of echocardiography (or NTproBNP > 620-1060pg/ml) 
- Male without ankle oedema – refer for echocardiography if BNP > 130-220 pg/ml (or NT-proBNP 
> 390-660 pg/ml) 
- Female with ankle oedema – refer for echocardiography if BNP > 100-180 pg/ml (or NT-proBNP 
> 190-520 pg/ml) 
 
 
 
MI = Myocardial Infarction 
BNP and NT-proBNP = B Type natriuretic peptide and N Terminal pro B Type natriuretic peptide 
Figure 1. Diagnostic algorithm recommended for use in primary care by the National 
Institute for Health and Clinical Excellence in England, 2003.18 
 
 
 
 
MCQs 
Heart failure prognosis is 
1) generally good 
2) worse for patients diagnosed in primary care than in hospital 
3) not linked to disease stage 
4) improved by ACE inhibitors and beta blocker therapies 
5) worsening across the population over time 
 
In the diagnosis of heart failure 
1) typical signs and symptoms are sufficiently reliable to establish disease 
2) ECG is sufficiently reliable to establish disease 
3) CXR is sufficiently reliable to establish disease 
4) natriuretic peptide assays are more reliable than ECG  
5) echocardiography is better for diagnosing preserved systolic function (diastolic) heart failure 
than for left ventricular systolic dysfunction heart failure 
 
Heart failure 
1) prevalence is between 2-3% of the adult population 
2) incidence is greater in women than men 
3) incidence and prevalence are predicted to fall 
4) prevalence is less certain for LVSD heart failure 
5) prevalence is lower in countries with high rates of coronary heart disease 
 
When considering natriuretic peptides 
1) they are fully evaluated in terms of their utility in heart failure diagnosis 
2) the cut-offs are the same for BNP and NT-proBNP assays 
3) both BNP and NT-proBNP are equally reliable in heart failure diagnosis 
4) adding an ECG to the assays adds incremental value 
5) they have no other value than in heart failure diagnosis 
 
The MICE clinical decision rule for heart failure diagnosis states 
1) refer for echocardiograpy, all women with BNP >210pg/ml (NT-proBNP >620 pg/ml) 
2) refer for echocardiography, all men with suspected heart failure  
3) refer for echocardiography, all men suspected of heart failure with ankle oedema  
4) test for natriuretic peptides, women suspected of heart failure with past myocardial infarction 
5)  test for natriuretic peptides, men with basal crepitations 
 
In the diagnosis of heart failure 
1) most guidelines advocate an echocardiographic left ventricular ejection fraction cut-off of 
<50% to determine heart failure 
2) the utilisation of echocardiography testing across Europe is high 
3) cardiac imaging is advocated for aetiology and staging even in those patients with confirmed 
diagnoses 
4) early diagnosis will not alter disease progression since no treatments delay progression 
5) echocardiography is a fully quantitative investigation     
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